HC Wainwright Has Negative View of MediWound FY2024 Earnings

MediWound Ltd. (NASDAQ:MDWD) – Analysts at HC Wainwright lowered their FY2024 earnings estimates for shares of MediWound in a report released on Wednesday, November 27th. HC Wainwright analyst S. Ramakanth now forecasts that the biopharmaceutical company will post earnings per share of ($2.61) for the year, down from their prior forecast of ($2.14). HC Wainwright currently has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.47) per share. HC Wainwright also issued estimates for MediWound’s Q4 2024 earnings at ($0.54) EPS, Q1 2025 earnings at ($0.56) EPS, Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.69) EPS, FY2026 earnings at ($1.87) EPS, FY2027 earnings at ($0.80) EPS and FY2028 earnings at $1.06 EPS.

Separately, StockNews.com upgraded MediWound to a “sell” rating in a research note on Monday, August 5th.

MediWound Trading Up 0.1 %

Shares of NASDAQ MDWD opened at $17.47 on Monday. The company has a market cap of $188.50 million, a P/E ratio of -6.02 and a beta of 0.83. MediWound has a 12-month low of $8.75 and a 12-month high of $24.00. The stock has a fifty day moving average price of $17.16 and a 200 day moving average price of $17.37.

Hedge Funds Weigh In On MediWound

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Investor AB acquired a new stake in MediWound during the 3rd quarter worth about $15,750,000. Rosalind Advisors Inc. lifted its position in MediWound by 22.3% during the 3rd quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company’s stock worth $11,343,000 after acquiring an additional 114,560 shares during the last quarter. ARK Investment Management LLC bought a new stake in shares of MediWound in the third quarter valued at approximately $1,806,000. State Street Corp lifted its stake in shares of MediWound by 219.6% in the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 45,529 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in shares of MediWound during the second quarter valued at approximately $342,000. 46.83% of the stock is owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.